Between group differences in secondary health related outcomes
| Mean (SD) score, sample size | Regression analysis* | |||
|---|---|---|---|---|
| Usual care | PhysioDirect | Difference (95% CI) | P | |
| Measure Yourself Medical Outcomes Profile† | ||||
| Baseline | 3.80 (0.99), 743 | 3.84 (0.99), 1504 | — | — |
| 6 weeks | 2.92 (1.21), 561 | 2.76 (1.28), 1101 | −0.19 (−0.30 to −0.07) | 0.001 |
| 6 months | 2.40 (1.38), 518 | 2.40 (1.43), 1033 | −0.02 (−0.16 to 0.11) | 0.73 |
| EQ-5D‡ | ||||
| Baseline | 0.56 (0.29), 731 | 0.53 (0.30), 1480 | — | — |
| 6 weeks | 0.64 (0.26), 554 | 0.64 (0.27), 1080 | 0.01 (−0.01 to 0.03) | 0.29 |
| 6 months | 0.69 (0.27), 508 | 0.69 (0.27), 1020 | 0.01 (−0.02 to 0.03) | 0.61 |
| Global improvement score‡ | ||||
| Baseline | NA | NA | NA | NA |
| 6 weeks | 3.54 (1.19), 552 | 3.69 (1.28), 1089 | 0.15 (0.02 to 0.28) | 0.02 |
| 6 months | 4.07 (1.40), 501 | 4.01 (1.44), 1001 | −0.08 (−0.23 to 0.08) | 0.32 |
| Response to treatment using OMERACT-OARSI criteria23ठ| ||||
| NA | NA | NA | NA | |
| 6 weeks | 124 (22.6)/550 | 306 (28.2)/1085 | 1.37 (1.08 to 1.75) | 0.01 |
| 6 months | 197 (38.6)/510 | 430 (41.8)/1029 | 1.14 (0.92 to 1.43) | 0.24 |
NA=not applicable; OMERACT=Outcome Measures in Rheumatology; OARSI=Osteroarthritis Research Society International; SD=standard deviation.
*Adjusting for baseline outcome, age, sex, referral problem, and primary care trust.
†Lower value indicates better outcome.
‡Higher value indicates better outcome.
§Data are no (%) of participants who responded/total sample size, and odds ratio (95% confidence interval).